title: A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies.
abstract: The purpose of the present study was to determine the maximally tolerated dose of thioTEPA given with fixed high-dose cyclophosphamide (CPA) and cisplatin (cDDP) followed by autologous bone marrow (ABM) with or without granulocyte colony-stimulating factor (G-CSF)-primed peripheral-blood progenitor cells (PBPCs) in patients with advanced malignancies. Patients were required to have histologically documented malignancies and adequate renal, hepatic, pulmonary, and cardiac function. CPA was given at 1,875 mg/m2 per day as a 1-h i.v. infusion for 3 consecutive days, and cDDP was given at 55 mg/m2 per day as a 24-h continuous i.v infusion over 3 days concurrently with CPA. ThioTEPA was given once as a 1-h i.v. infusion (300-900 mg/m2) either following (the first 13 patients) or prior to CPA and cDDP. In all, 31 patients received PBPCs. A total of 46 patients were treated. There were 6 deaths among the 15 patients who did not receive PBPCs (13 received thioTEPA following CPA and cDDP). Among the other 31 patients who received PBPCs (all of whom also received thioTEPA prior to CPA and cDDP), there were 4 deaths, all involving patients with refractory ovarian carcinoma. The main toxicities were mucositis, esophagitis, hepatotoxicity, and nephrotoxicity. The median time required to achieve an absolute neutrophil count of 500 microliter was 10 days (range, 9-12 days) for those who received PBPCs and 15 days (range, 15-34 days) for those who did not receive PBPCs. Altogether, 47% of the major organ toxicities (grades 3 and 4 renal, hepatic, and cardiac toxicities) occurred among the 15 patients who did not receive PBPCs, although these patients received thioTEPA at the lowest 2 dose levels. There were 3 complete responses and 22 partial responses among 35 evaluable patients (overall response rate, 71%), with the median duration of response being 3.5 months (range, 2-17 months). The maximally tolerated dose of thioTEPA was 600 mg/m2 given as a 1-h i.v. infusion on the day prior to CPA and cDDP administration, The combination of high-dose CPA, cDDP, and thioTEPA is a well-tolerated regimen when thioTEPA is given prior to CPA and cDDP and when the combination also includes PBPCs in addition to ABM. This regimen is active in a variety of malignancies.
authors.affiliation: Duke Bone Marrow Transplant Program, Duke University Medical Center, Durham NC 27710, USA.
authors.forename: A M
authors.initials: AM
authors.lastname: Hussein
authors.forename: W P
authors.initials: WP
authors.lastname: Petros
authors.forename: M
authors.initials: M
authors.lastname: Ross
authors.forename: J J
authors.initials: JJ
authors.lastname: Vredenburgh
authors.forename: M L
authors.initials: ML
authors.lastname: Affrontil
authors.forename: R B
authors.initials: RB
authors.lastname: Jones
authors.forename: E J
authors.initials: EJ
authors.lastname: Shpall
authors.forename: P
authors.initials: P
authors.lastname: Rubin
authors.forename: M
authors.initials: M
authors.lastname: Elkordy
authors.forename: C
authors.initials: C
authors.lastname: Gilbert
authors.forename: C
authors.initials: C
authors.lastname: Gupton
authors.forename: M J
authors.initials: MJ
authors.lastname: Egorin
authors.forename: J
authors.initials: J
authors.lastname: Soper
authors.forename: A
authors.initials: A
authors.lastname: Berchuck
authors.forename: D
authors.initials: D
authors.lastname: Clarke-Person
authors.forename: D A
authors.initials: DA
authors.lastname: Berry
authors.forename: W P
authors.initials: WP
authors.lastname: Peters
mesh_terms: D000328:Adult; D016026:Bone Marrow Transplantation; D002945:Cisplatin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy*; D013852:Thiotepa / Q000008:administration & dosage* / Q000493:pharmacokinetics
chemical_list: D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide; D013852:Thiotepa; D002945:Cisplatin